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Abstract
Objective.—Knowledge of one’s gene status for adult onset conditions provides opportunity to 
make advance end-of-life (EOL) plans. The purposes of these analyses were to: 1) determine the 
prevalence of EOL plans, including advance directives (ADs) among persons across three stages of 
Huntington disease (HD); and 2) examine factors associated with having ADs in this sample.
Methods.—Data are from 503 participants in the Huntington Disease Quality of Life study. 
Participants completed an online health-related quality of life survey that included questions 
regarding EOL planning and self-reported HD symptoms. Frequencies were calculated for EOL 
planning by HD stage. Bivariate analysis and logistic regression were used to identify variables 
associated with having ADs.
Results.—38.2% of participants stated they had ADs and fewer than half had other EOL plans. 
Being older, increased HD stage, more years of education, lower anxiety, more swallowing 
symptoms, and higher meaning and purpose were associated with having ADs.
Conclusion.—The prevalence of ADs in our sample is comparable to the general US population, 
but surprisingly low considering the severity and long disease course of HD.
Practice Implications.—Health care providers should develop specific interventions early in 
the disease process to increase ADs in this population.
Correspondence to: Nancy R. Downing, Texas A&M College of Nursing, 8447 State Highway 47, Bryan, TX, 77807, USA. Tel: 
979-436-0157; Fax: 979-436-0098. downing@tamhsc.edu. 
The authors report no competing financial interests.
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Introduction
Huntington disease (HD) is a devastating neurodegenerative disease for which there is 
palliative treatment, but no cure. The disease is caused by an autosomal dominant 
trinucleotide CAG repeat expansion on the HTT gene. Symptoms typically begin in middle 
age, and include progressive decline in cognitive, behavioral, motor, and day-to-day 
functioning [1] that significantly impact health-related quality of life (HRQOL) [2, 3]. 
Progression to dementia is inexorable; death occurs approximately 17–20 years following 
motor diagnosis [1]. Presymptomatic genetic testing has been available since the discovery 
of the HTT gene mutation in 1993 [4]. If a patient does not undergo presymptomatic genetic 
testing, diagnoses are made based on consistent family history with typical motor signs (e.g. 
chorea) or confirmation by genetic testing [5]. One of the benefits of knowing one’s gene 
status for an adult onset disease, especially one that involves dementia, is the ability to make 
advance end of life (EOL) decisions while one still has the cognitive capacity [6].
Advance directives (ADs), including living wills, health care powers of attorney, or health 
care directives, are legal documents that state an individual’s preferences for medical 
treatment and to appoint a surrogate to make decisions on their behalf if they become 
incapacitated [7]. Advance directives are effective in decreasing unwanted hospitalization 
and unwanted life-sustaining treatment, and increasing the use of palliative and hospice care 
[8]. Since HD affects decision-making capacity in later stages, it is imperative that EOL 
discussions occur early in the disease course [9]. A working group on EOL planning needs 
for people with HD funded by the Robert Wood Johnson Foundation recommended 
healthcare providers educate persons with HD on the need to develop and complete ADs 
[10].
Despite a recognized need, the prevalence of ADs among persons with HD in the US is not 
known. People usually have prior knowledge of their HD risk because they have affected 
family members or have undergone HD genetic testing. Knowledge of gene status for adult 
onset conditions provides the opportunity to make advance EOL plans [6]. People with HD 
might be more likely than the general population to have ADs since people with chronic 
diseases in the general US population are more likely to have ADs than those without 
chronic disease [11]. The purposes of these analyses were to: 1) examine the prevalence of 
ADs and other EOL plans in a large sample of people at three stages of HD; and 2) examine 
the demographic, clinical and self-reported HRQOL factors associated with having ADs in 
this sample.
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Methods
Setting/Sample
Data for this analysis come from the first phase of the Huntington Disease Quality of Life 
(HDQLIFE) Study. The purpose of the HDQLIFE study is to develop computer adaptive 
tests (CATs) and short forms (SF) to assess patient-reported HRQOL for persons with HD 
[12–15]. Individuals with prodromal or manifest HD (N=503) 18 years and older and able to 
read and understand English participated in the first phase of the study (12/19/2012–
12/14/2014). Participants were recruited at a variety of specialized treatment centers across 
the US (University of Michigan, University of Iowa, University of California - Los Angeles, 
Indiana University, Johns Hopkins University, Rutgers University, Struthers Parkinson’s 
Center, Washington University at St. Louis, University of California – San Francisco, and 
the Cleveland Clinic), from the PREDICT-HD study [16], the National Research Roster for 
Huntington’s Disease [17], and articles and advertisements in HD newsletters and websites. 
This study was approved by all participating institutions’ human subjects research boards 
and all participants provided informed consent.
There were 505 participants in the HDQLIFE study. Data regarding HD stage was missing 
for two participants. Thus, analyses that included comparisons between HD stage included 
503 participants stratified into three HD stages: prodromal (n=197), early (n=193), and late 
(n=113). Prodromal stage included individuals who did not have a clinical diagnosis of HD 
but had a confirmed CAG repeat ≥36, meaning they will eventually develop HD if they have 
a normal lifespan; manifest HD participants (n=308) had a neurologist-confirmed HD 
clinical diagnosis or received a ≥99% confidence rating on the motor component of the 
Unified Huntington’s Disease Rating Scale (UHDRS), indicating unequivocal signs of HD. 
Staging of HD for participants with manifest HD was classified according to the UHDRS 
Total Functional Capacity (TFC) scale [18], a clinician-administered scale evaluating day-to-
day function regarding occupation, finances, domestic chores, activities of daily living, and 
care level. Scores range from 0 (low functioning) to 13 (high functioning). Participants were 
classified as early stage (7–13) or late stage HD (0–6).
Assessments
Participants completed the HDQLIFE protocol, including questions regarding EOL 
planning, including ADs, living wills, healthcare power of attorney, resuscitation preference, 
conversations about death and dying, location of death preference, nursing home care, 
palliative care, and hospice care. All participants were asked to answer questions about all 
these items. Due to confusion regarding the definitions of these terms in the general public 
that might be relevant in this study, the focus of our analysis was on comparison of 
participants with and without ADs. Information regarding ADs was assessed by a single 
item, “Advance directive (also known as a Living will).” Participants were instructed to 
choose the response that best described where they stood regarding ADs: “I have not thought 
about getting an advance directive;” “I have thought about getting an advance directive;” “I 
have taken steps to obtain an advance directive;” and “I have an advance directive.” Similar 
response choices were provided for other items.
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Participants also completed newly developed self-report assessments for the presence of HD 
symptoms, concerns about HD, impact of symptoms, and concerns on HRQOL. We used SF 
versions of these measures that were created using item response analyses: HDQLIFE 
Speech Difficulties SF [15], HDQLIFE Swallowing Difficulties SF [15], HDQLIFE Chorea 
SF [13], HDQLIFE Concern with Death & Dying SF, and HDQLIFE Meaning & Purpose 
SF [12]. All HDQLIFE measures generate T scores on a T-metric relative to other 
individuals with HD. T-scores are standardized scores with mean of 50 and standard 
deviation of 10; higher scores indicate more of the construct being measured (e.g., more 
speech difficulty, or greater meaning and purpose). Participants also completed the Patient-
Reported Outcomes Measurement Information System (PROMIS) Anxiety SF [19]; higher 
scores indicate more anxiety and is scored on a T-metric with the general population as 
referent.
Trained clinicians administered the UHDRS Total Motor Score (TMS) in person. 
Participants completed patient-reported outcome (PRO) measures through PROMIS 
Assessment Center (https://www.assessmentcenter.net) at a designated computer or tablet 
during the study visit or were asked to complete it within two weeks of the study visit. 
Participants and those assisting them were instructed that responses were to come directly 
from participants (i.e., assistance was limited to logging into the online study platform, 
reading questions aloud, and/or clicking response options, when needed).
Data Analysis
Participants were classified as “with ADs” when participants selected the response option “I 
have an advance directive;” all other responses to that question were classified as “without 
ADs.” We calculated descriptive statistics for demographic variables (age, gender, race, 
ethnicity, marital status, years of education), and scores on HDQLIFE and PROMIS 
measures. Analyses of variance (ANOVA) were used to compare demographic differences 
between prodromal, early, and late stages. Sociodemographic and clinical characteristics of 
participants with and without ADs were compared using chi-square for categorical data: 
gender, race, marital status, and HD stage; independent t-tests were conducted to compare 
continuous data: age, years of education, and self-report SF (HDQLIFE Chorea, HDQLIFE 
Speech, HDQLIFE Swallowing, HDQLIFE Concern with Death & Dying, HDQLIFE 
Meaning & Purpose, and PROMIS Anxiety). We used an alpha of .05 for all t-tests. We used 
Bonferroni adjusted alpha levels for the variables groups demographics (.05/5 variables = .
01) and HDQLIFE/PROMIS measures (.05/6 variables = .008). We did not correct for all 
variables together (.05/12 = .004) because this is the first known analysis on this topic and 
we did not want to miss potentially important differences that could be further examined in 
future studies.
In the logistic regression model, variables that were significantly different (p < 0.05) 
between participants with and without ADs in chi-square and t-tests were included to 
determine which factors independently increased odds of having ADs: age, HD stage, 
education, HDQLIFE Concern for Death & Dying, HDQLIFE Meaning & Purpose, and 
PROMIS Anxiety. Age and years of education were entered as continuous variables and T 
scores were used for HDQLIFE and PROMIS Anxiety. HDQLIFE Swallowing was not 
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included because the difference between those with ADs (53.83) and without ADs (52.78) 
was unlikely to be clinically meaningful. Although not significant in t-tests, HDQLIFE 
Concern for Death & Dying was included in the model because this psychological variable 
might impact whether a person has ADs.
Results
Participant demographics are shown in Table 1. The age range of participants was 18–81, 
mean 49.04 years. Most participants were White (96%) and not Hispanic (93.7%). There 
were some notable differences in ANOVA comparisons between prodromal vs. early and 
prodromal vs. late stage groups on some variables: There were differences in age, F (2, 500) 
= 44.377, p < .001, and years of education, F (2,498) = 15.415, p < .001, with participants in 
the prodromal stage being younger and having more years of education than those in the 
early and those in the late stage. More prodromal stage participants were married compared 
to early stage, X2 (2, 502) = 8.12, p = .017.
Overall, 38.2% of participants reported they had ADs. Frequencies and percentages for ADs 
and associated EOL planning are presented in Table 2 for each HD stage. In general, higher 
percentages of participants in the late stage had ADs and other EOL plans.
Chi-square results (Table 3) indicated significant differences between participants with and 
without ADs for HD stage, X2 (2, n=503) = 9.01. Participants in late stage HD were more 
likely to have ADs than those in prodromal or early stage HD. In t-test analyses (Table 3), 
there were significant differences between participants with and without AD based on age, 
t(503) = 8.63, p = <0.001; years of education, t(501) = −2.89, p=0.004; and HDQLIFE 
Meaning & Purpose, t(493) = 2.92, p =0.004. Participants were more likely to have ADs if 
they were older, had more years of education, and higher scores on HDQLIFE Meaning and 
Purpose and HDQLIFE Swallowing, and lower scores on PROMIS Anxiety, although 
Swallowing and Anxiety were not significant after correcting for multiple comparisons.
The multivariable logistic regression model explained 72.4% of the variance in predicting 
whether a participant had ADs (Table 4). For each year of age, participants had 6% higher 
odds of having ADs (odds ratio [OR] 1.06; 95% CI: 1.03, 1.08). Participants in the late stage 
had almost three times higher odds of having ADs than the prodromal stage (OR 2.87, 95% 
CI: 1.35, 6.14). Each year of education increased the odds of having ADs by 12% (OR 1.12, 
95% CI: 1.02, 1.22). Early stage HD, HDQLIFE Concern for Death & Dying, HDQLIFE 
Meaning & Purpose, and PROMIS Anxiety were not associated with higher odds of having 
ADs.
Discussion
Huntington disease is a devastating disease that causes dementia and premature death. 
People usually have many years to engage in EOL planning since the disease course spans 
up to 20 years. We report data on the prevalence of ADs among a large sample of people 
with HD in the US. Among the 503 participants in this analysis, 38.2% responded they had 
ADs. This exceeds 31.3% of participants in a study of persons with HD in the Netherlands 
[9], and 26.3% of people in the general US population [11]; however, it is lower than 47.3% 
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of participants over 60 in the US with two or more chronic conditions [20]. Considering the 
severity of HD and its association with premature mortality, it is surprising only 38.2% of 
participants had ADs.
Older age has consistently been associated with having ADs in prior studies, as it was in 
ours [9, 11, 20]. Our sample is relatively young (mean age = 49.04). When age is 
considered, prevalence of ADs may be higher than among persons of similar ages without 
HD. For example, in a study examining prevalence of ADs in the general population [11], 
18.2% of participants ages 18–54 had ADs. In that light, 38.2% of participants in our study 
with ADs appears relatively high. On the other hand, it is reasonable to assume that people 
who know they face significant premature morbidity and death would have even higher 
prevalence of ADs. Self-reported HD symptoms, including the hallmark symptom chorea, 
were not associated with increased ADs in our study. Having more self-reported swallowing 
symptoms was associated with having ADs in bivariate analyses, but the difference in 
symptoms between those with and without ADs was very small and was significant after 
correcting for multiple comparisons. There are some previously documented phenomena in 
HD that might explain why prevalence of ADs was not as high as expected. For example, 
decreased awareness of disease symptoms can occur in HD [21], and a tendency for persons 
with HD to normalize symptoms [22]. While participants in late stage HD were almost three 
times more likely than participants in the prodromal stage to have ADs, this could be related 
more to age than presence of HD symptoms. Our findings suggest that persons with the HD 
gene mutation are similar to those without HD with regard to EOL planning, despite 
knowing more about their potential fate. The HDQLIFE study was not designed specifically 
to examine this issue, however; thus, it is possible that other designs might better reveal the 
motivations of persons with HD to make EOL plans.
Participants with late stage HD in our study might have being diagnosed based on family 
history and HD symptoms and not have had presymptomatic testing, either by choice or 
because presymptomatic testing was not available before they developed symptoms. People 
who get tested presymptomatically might be different from people who learn their gene 
status through clinical diagnosis. In our study, participants in the prodromal stage had more 
years of education than those in early and late stage HD, and more years of education 
slightly increased the odds of having ADs. Higher education level has previously been 
associated with having EOL plans in both HD and non HD samples [9, 11, 23–25]. The 
relationship between education and having ADs might be mediated by literacy [23]. The use 
of jargon, including multiple terms referring to ADs, might not clearly describe the intent 
and usefulness of ADs to patients with lower literacy.
Participants in our study with higher self-reported scores on the PROMIS Anxiety SF were 
less likely to have ADs in the bivariate analysis, although it was not significant after 
correcting for multiple comparisons and it was not a predictor of having ADs in the logistic 
regression model. In our study, HDLIFE Concern for Death & Dying was not significantly 
associated with having ADs. Fear of death, anxiety and concern might, in fact, lead people 
to avoid EOL planning in an effort to avoid increasing anxiety [26]. Therefore, it would still 
be important to assess for anxiety, especially disease- and death-related anxiety, in future 
studies.
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A potential benefit of presymptomatic HD genetic testing is the ability to plan for the future 
[27, 28]. Participants in the prodromal stage in our study had undergone presymptomatic HD 
genetic testing, yet had the lowest prevalence of ADs and other EOL plans in our sample. 
Thus, genetic testing did not appear to strongly impact making EOL planning in the 
prodromal stage. However, we cannot exclude that many of these participants will make 
EOL plans while still cognitively able to do so.
Our study has some limitations that might impact generalizability of our findings. Race and 
ethnicity are limitations because the vast majority of persons with HD in the US are of 
European descent and non-Hispanic; prevalence rates are higher in North America, Europe 
and Australia, compared to Asia [34]. Advance directives, living will, and other EOL 
terminology such as palliative care were not defined in the HDQLIFE online survey. Given 
that literacy is an identified barrier to ADs [23], participants might have responded without 
having a clear understanding of these terms. Participants were encouraged to answer all 
questions but were not forced to answer items. We did not include a response option to 
indicate when participants did not understand a question. In the future, we could consider 
defining these terms.
Our sample included more participants in prodromal and early stages than late stage. This is 
understandable, as decreased cognitive ability in later stages of HD could preclude capacity 
to provide informed consent. Participants in the prodromal stage in our study might not be 
representative of most people at risk for HD because they had independently undergone 
presymptomatic HD testing while the uptake of presymptomatic genetic testing for HD is 
estimated to be under 20% [35]. Many participants were recruited from sites that have HD 
Centers of Excellence (COE), which are affiliated with the Huntington Disease Society of 
America (HDSA). The COE provide specialized care for people with HD and the HDSA has 
published materials on ADs available to members. Therefore, our sample might include 
people more likely to seek and receive information regarding HD. While prevalence of ADs 
was lower than expected, our participants might be more likely to have ADs than people 
who have not undergone genetic testing, do not have access to a COE, or do not participate 
in HD-related research.
We cannot exclude the possibility that family members answered items on behalf of 
participants, despite instructions that answers should come directly from participants. The 
purpose of the HDLIFE study is to develop a HRQOL measure for people with HD; the 
examination of factors associated with having ADs was not a primary aim. Therefore, there 
are several variables associated with having ADs that we did not measure that have been 
found to be associated with ADs, including knowledge of ADs, literacy, self-efficacy, 
religiosity, and illness-related fear [20, 23, 26, 36–38].
Despite the 2004 recommendations of the Huntington’s Disease Peer Workgroup, our 
findings suggest that prevalence of ADs is low in this population. Interventions designed to 
increase patient-provider discussions of ADs are effective in increasing development of and 
use of ADs [29]. An important question remains whether health care providers provide 
adequate patient education to persons with HD regarding ADs, and at an appropriate level of 
literacy. Having ADs is often not considered an important issue in HD until the disease 
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symptoms have progressed significantly and the patient and family are considering long-
term care placement. Unfortunately, this can result in the patient being unable to voice their 
preferences due to advancing dementia [30].
There is a recognized need for EOL planning for patients with HD to reduce risk of 
emotional distress from unwanted, aggressive and costly EOL care [10, 31]. While we 
examined factors associated with having ADs among persons with HD, future studies should 
identify patient and health care provider barriers to creation of ADs in this population. Data 
from our study could inform development of specific interventions to increase prevalence of 
ADs and EOL planning. A promising method involves using vignettes to illustrate disease-
specific EOL scenarios to help patients work through their preferences [32]. This could be 
adapted for use in HD by providing patients with scenarios based on common causes of 
death in persons with HD. This technique could aid literacy by explaining often 
misunderstood medical terms and end-of-life interventions such as cardiopulmonary 
resuscitation, feeding tubes, and ventilators [33]. Medicare reimbursement for EOL 
discussions is a positive step, although these discussions should begin long before patients 
with HD become Medicare eligible. Prevalence of ADs and EOL plans is surprisingly low 
considering the severity and long disease course of HD. Health care providers should 
actively educate and assist patients with HD in making ADs and EOL plans to specify 
treatment preferences while they still have the cognitive ability.
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Acronyms
AD Advance directives
CAT Computer adaptive tests
Downing et al. Page 8
Am J Hosp Palliat Care. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
COE Centers of Excellence
EOL End of life
HD Huntington disease
HDQLIFE Huntington Disease Quality of Life study
HRQOL Health-related quality of life
PRO Patient-reported outcome
PROMIS Patient-Reported Outcomes Measurement Information System
SF Short form
TFC Total Functional Capacity scale
TMS Total motor score
UHDRS United Huntington Disease Rating Scale
References
[1]. Walker FO . Huntington’s disease. Lancet, 2007 369(9557): p. 218–28.17240289
[2]. Carlozzi NE , Tulsky DS . Identification of Health-Related Quality of Life (HRQOL) Issues 
Relevant to Individuals with Huntington Disease. J Health Psychol, 2012.
[3]. Ready RE , et al. Patient and caregiver quality of life in Huntington’s disease. Mov Disord, 2008 
23(5): p. 721–6.18175350
[4]. The Huntington’s Disease Collaborative Research Group, A novel gene containing a trinucleotide 
repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell, 1993 72: p. 
971–983.8458085
[5]. Reilmann R , Leavitt BR , Ross CA . Diagnostic criteria for Huntington’s disease based on natural 
history. Mov Disord, 2014 29(11): p. 1335–41.25164527
[6]. Neumann PJ , et al. Public attitudes about genetic testing for Alzheimer’s disease. Health Aff 
(Millwood), 2001 20(5): p. 252–64.11558711
[7]. Regulations C.o.F. , Advance Directives, in 489.100.
[8]. Brinkman-Stoppelenburg A , Rietjens JA , van der Heide A . The effects of advance care planning 
on end-of-life care: a systematic review. Palliat Med, 2014 28(8): p. 1000–25.24651708
[9]. Booij SJ , et al. Thinking about the end of life: a common issue for patients with Huntington’s 
disease. J Neurol, 2014 261(11): p. 2184–91.25178513
[10]. Dubinsky R , et al. Lifting the veil of Huntington’s disease: Recommendations to the field from 
the Huntington’s disease Peer Workgroup. 2004, Roberrt Wood Johnson Foundation: Princeton, 
NJ.
[11]. Rao JK , et al. Completion of advance directives among U.S. consumers. Am J Prev Med, 2014 
46(1): p. 65–70.24355673
[12]. Carlozzi NE , et al. New measures to capture end of life concerns in Huntington disease: 
Meaning and Purpose and Concern with Death and Dying from HDQLIFE (a patient-reported 
outcomes measurement system). Qual Life Res, 2016.
[13]. Carlozzi NE , et al. The development of a new computer adaptive test to evaluate chorea in 
Huntington disease: HDQLIFE Chorea. Qual Life Res, 2016.
[14]. Carlozzi NE ., et al., HDQLIFE: development and assessment of health-related quality of life in 
Huntington disease (HD). Qual Life Res, 2016.
Downing et al. Page 9
Am J Hosp Palliat Care. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
[15]. Carlozzi NE , et al. HDQLIFE: the development of two new computer adaptive tests for use in 
Huntington disease, Speech Difficulties, and Swallowing Difficulties. Qual Life Res, 2016.
[16]. Paulsen JS , et al. Clinical and Biomarker Changes in Premanifest Huntington Disease Show 
Trial Feasibility: A Decade of the PREDICT-HD Study. Front Aging Neurosci, 2014 6: p. 
78.24795630
[17]. Hanauer DA , et al. Supporting information retrieval from electronic health records: A report of 
University of Michigan’s nine-year experience in developing and using the Electronic Medical 
Record Search Engine (EMERSE). J Biomed Inform, 2015 55: p. 290–300.25979153
[18]. Huntington Study Group, Unified Huntington’s Disease Rating Scale: reliability and consistency. 
Mov Disord, 1996 11(2): p. 136–42.8684382
[19]. Cella D , et al. The Patient-Reported Outcomes Measurement Information System (PROMIS): 
progress of an NIH Roadmap cooperative group during its first two years. Med Care, 2007 45(5 
Suppl 1): p. S3–S11.
[20]. Chiu C , et al. “Doctor, Make My Decisions”: Decision Control Preferences, Advance Care 
Planning, and Satisfaction With Communication Among Diverse Older Adults. Journal of Pain 
and Symptom Management, 2016 51(1): p. 33–40.26342727
[21]. McCusker EA , et al. Unawareness of motor phenoconversion in Huntington disease. Neurology, 
2013 81(13): p. 1141–1147.23966256
[22]. Downing NR . Williams JK , Paulsen JS . Couples’ attributions for work function changes in 
prodromal Huntington disease. J Genet Couns, 2010 19(4): p. 343–52.20309619
[23]. Waite KR , et al. Literacy and race as risk factors for low rates of advance directives in older 
adults. J Am Geriatr Soc, 2013 61(3): p. 403–6.23379361
[24]. Lingler JH , et al. Frequency and correlates of advance planning among cognitively impaired 
older adults. Am J Geriatr Psychiatry, 2008 16(8): p. 643–9.18669942
[25]. Triplett P , et al. Content of advance directives for individuals with advanced dementia. J Aging 
Health, 2008 20(5): p. 583–96.18625761
[26]. Dobbs D , et al. Religiosity and Death Attitudes and Engagement of Advance Care Planning 
Among Chronically Ill Older Adults. Research on Aging, 2012 34(2): p. 113–130.
[27]. Daack-Hirsch S , et al. ‘Information is information’: a public perspective on incidental findings in 
clinical and research genome-based testing. Clin Genet, 2013 84(1): p. 11–8.23590238
[28]. Foster M , Mulvihill J , and Sharp R , Evaluating the utility of personal genomic information. 
Genet Med, 2009 11(8): p. 570–4.19478683
[29]. Houben C et al. Efficacy of advance care planning: a systematic review and meta-analysis. J Am 
Med Dir Assoc, 2014 15(7): p. 477–89.24598477
[30]. Moskowitz CB , Marder K . Palliative care for people with late-stage Huntington’s disease. 
Neurol Clin, 2001 19(4): p. 849–65.11854103
[31]. Tang ST , et al. Preferences for Life-Sustaining Treatments and Associations With Accurate 
Prognostic Awareness and Depressive Symptoms in Terminally Ill Cancer Patients’ Last Year of 
Life. J Pain Symptom Manage, 2016 51(1): p. 41–51 e1.26386187
[32]. Michael N , O’Callaghan C , Clayton J M . Exploring the utility of the vignette technique in 
promoting advance care planning discussions with cancer patients and caregivers. Patient Educ 
Couns, 2016 99(8): p. 1406–12.27021780
[33]. Porensky EK , Carpenter BD . Knowledge and perceptions in advance care planning. J Aging 
Health, 2008 20(1): p. 89–106.18252936
[34]. Pringsheim T , et al. The incidence and prevalence of Huntington’s disease: a systematic review 
and meta-analysis. Mov Disord, 2012 27(9): p. 1083–91.22692795
[35]. Morrison PJ , Harding-Lester S , Bradley A . Uptake of Huntington disease predictive testing in a 
complete population. Clin Genet, 2011 80(3): p. 281–6.20880124
[36]. Alano GJ , et al. Factors influencing older adults to complete advance directives. Palliat Support 
Care, 2010 8(3): p. 267–75.20875170
[37]. Ekdahl AW , et al. Are elderly people with co-morbidities involved adequately in medical 
decision making when hospitalised? A cross-sectional survey. BMC Geriatr, 2011 11: p. 
46.21851611
Downing et al. Page 10
Am J Hosp Palliat Care. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
[38]. Garand L , et al. Incidence and predictors of advance care planning among persons with cognitive 
impairment. Am J Geriatr Psychiatry, 2011 19(8): p. 712–20.21785291
Downing et al. Page 11
Am J Hosp Palliat Care. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Downing et al. Page 12
Table 1.
Participant demographics by HD stage
Stage
Variable Prodromal (n=197) Early (n=193) Late (n=113) All (n=503)
Age 42.80 51.98a 54.95a 49.04
 Mean (SD) (12.17) (12.41) (12.04) (13.23)
Years of Education 15.91 14.69a 14.24a 15.07
 Means (SD) (2.94) (2.78) (2.64) (2.89)
Gender (%)
Female 64.0 45.1 41.6 59.2
Male 36.0 54.9 58.4 40.8
Race (%)
White 97.5 96.4 92.9 96.0
Other 2.0 3.6 7.1 3.8
Unknown 0.5 0.0 0.0 0.2
Ethnicity (%)
Not Hispanic or Latino 92.4 92.7 94.3 93.7
Hispanic or Latino 1.5 4.1 0.9 2.4
Not Provided 6.1 3.1 1.8 4.0
Marital Status (%) Married 67.0 52.8a 62.8 60.8
a
= significantly different than prodromal, all p<0.05
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Table 2.
End of life planning by HD stage
HD Stage Frequency Number (%)
Prodromal Early Stage Late Stage Total
Advance directive
I have not thought about getting an advance directive 35 (17.8) 28 (14.5) 14 (12.4) 77 (15.3)
I have thought about getting an advance directive 83 (42.1) 75 (38.9) 22 (19.5) 182 (36)
I have taken steps to obtain an advance directive 20 (10.2) 18 (9.3) 15 (13.3) 53 (10.5)
I have an advance directive 59 (29.9) 72 (37.3) 62 (54.9) 193 (38.2)
Total 197 193 113 503
Living will
I have not thought about preparing a living will 30 (15.3) 29 (15.2) 18 (16.1) 78 (15.6)
I have thought about preparing a living will 90 (45.9) 77 (40.3) 22 (19.6) 190 (37.9)
I have taken steps to prepare a living will 18 (9.2) 14 (7.3) 9 (8.0) 41 (8.2)
I have a living will 58 (29.6) 71 (37.2) 63 (56.3) 192 (38.3)
Total 196 193 112 501
Healthcare power of attorney (POA)
I have not thought of getting a healthcare POA 55 (27.9) 32 (16.6) 14 (12.4) 102 (20.2)
I have thought of getting a healthcare POA 71 (36.0) 64 (33.2) 16 (14.2) 152 (30.1)
I have taken steps to identify a healthcare POA 21 (10.7) 19 (9.8) 11 (9.7) 51 (10.1)
I have a healthcare POA 47 (23.9) 70 (36.3) 69 (61.1) 186 (36.8)
Total 194 185 113 492
Resuscitation preference
I have not thought about my preference for resuscitation if I stop breathing 55 (28.1) 49 (25.8) 26 (23.2) 131 (26.2)
I have thought about my preference for resuscitation if I stop breathing 66 (33.7) 60 (31.6) 27 (24.1) 154 (30.8)
I have made my preference for resuscitation clear to others if I stop breathing 75 (38.3) 81 (42.6) 59 (52.7) 215(43)
Total 196 190 112 500
Conversations about death and dying
I have not thought about starting a conversation about death with my friends, family, 
or members in the community (e.g., church/synagogue) 78 (39.6) 49 (25.4) 48 (42.5) 175 (34.7)
I have thought about starting a conversation about death with my friends, family or 
members in the community 27 (13.7) 45 (23.3) 16 (14.2) 186 (36.8)
I have taken steps to start a conversation about death with my friends, family or 
members in the community 33 (16.8) 32 (16.6) 11 (9.7) 28 (5.5)
I have had a conversation about death with my friends, family or members in the 
community 56 (28.4) 64 (33.2) 37 (32.7) 53 (10.5)
Total 194 190 112 496
Location of death preferences (i.e., at home, in the hospital)
I have not thought about where I would like to die 96 (49.5) 85 (45) 48 (42.9) 230 (46.3)
I have thought about where I would like to die 75 (38.7) 77 (40.7) 33 (29.5) 186 (37.4)
I have taken steps to arrange where I would like to die 10 (5.2) 10 (5.3) 8 (7.1) 28 (5.6)
I have identified a location where I would like to die 13 (6.7) 17 (9.0) 23 (20.5) 53 (10.7)
Total 194 189 112 497
Nursing home care
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HD Stage Frequency Number (%)
Prodromal Early Stage Late Stage Total
I have not thought about nursing home care 116 (59.2) 93 (48.9) 52 (46) 263 (52.5)
I have thought about nursing home care 61 (31.1) 73 (38.4) 28 (24.8) 162 (32.3)
I have taken steps to arrange nursing home care 13 (6.6) 11 (5.8) 6 (5.3) 30 (6.0)
I have established nursing home care 6(3.1) 13 (6.8) 27 (23.9) 46 (9.2)
Total 196 193 113 501
Palliative care
I have given little or no thought to palliative care 116 (60.4) 101 53.7) 63 (56.8) 282 (57.0)
I have thought about palliative care 69 (35.9) 72 (38.3) 23 (20.7) 164 (33.4)
I have taken steps to arrange palliative care 7 (3.6) 12 (6.4) 7 (6.3) 26 (5.3)
I am receiving palliative care 0 (0) 3 (1.6) 18 (16.2) 21 (4.3)
Total 192 188 111 493
Hospice care
I have not thought about hospice care 119 (61.3) 101(52.9) 65 (57.5) 286 (57.2)
I have thought about hospice care 73 (37.6) 81 (42.4) 42 (37.2) 197 (39.4)
I have taken steps to arrange hospice care 2 (1.0) 9 (4.7) 5 (4.4) 16 (3.2)
I am receiving hospice care 0 0 1 (0.9) 1 (0.2)
Total 194 191 113 500
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Table 3.
Bivariate analyses results comparing participants with and without advance directives
Variable Statistic p value
Age t(503)=−8.632
<0.001a
Gender X2 (1, n= 505) = 0.63 0.426
Race X2 (1, n= 504) = 2.48 0.115
Marital status X2 (1, n= 504) = 3.84 0.050
HD stage X2 (2, n= 503) = 9.01 <0.001a
Years Education t(501) = −2.89 0.004a
HDQLIFE Chorea SF t(490) =−1.66 0.097
HDQLIFE Speech SF t(499)=−1.51 0.132
HDQLIFE Swallowing SF t(498)=−2.110 0.035
HDQLIFE Concern for Death & Dying SF t(491 )=1.943 0.053
HDQLIFE Meaning & Purpose SF t(493)=−2.915 0.004a
PROMIS Anxiety SF t(330)=2.353 0.019
aNote: = remains significant after Bonferroni Correction,SF = short form
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Table 4.
Multivariable logistic regression model
Factor Odds Ratio 95% Confidence Interval
Age 1.06 1.03 , 1.08
Early Stage HD* 1.45 0.76 , 2.76
Late Stage HD* 2.87 1.35 , 6.14
Years of Education 1.12 1.02 , 1.22
HDQLIFE Concern for Death & Dying SF 0.98 0.95 , 1.02
HDQLIFE Meaning & Purpose SF 1.01 0.99 , 1.05
PROMIS Anxiety SF 0.99 0.96 , 1.02
*Note: Prodromal group is the index group; SF = short form; all p values <0.02.
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